1. Home
  2. LAES vs FBRX Comparison

LAES vs FBRX Comparison

Compare LAES & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SEALSQ Corp

LAES

SEALSQ Corp

HOLD

Current Price

$2.73

Market Cap

606.5M

Sector

Technology

ML Signal

HOLD

Logo Forte Biosciences Inc.

FBRX

Forte Biosciences Inc.

HOLD

Current Price

$26.74

Market Cap

487.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LAES
FBRX
Founded
2022
N/A
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
606.5M
487.2M
IPO Year
2022
2017

Fundamental Metrics

Financial Performance
Metric
LAES
FBRX
Price
$2.73
$26.74
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$4.00
$67.00
AVG Volume (30 Days)
12.8M
368.0K
Earning Date
03-31-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.30
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$93.36
N/A
Revenue Next Year
$43.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.99
$6.50
52 Week High
$8.71
$35.80

Technical Indicators

Market Signals
Indicator
LAES
FBRX
Relative Strength Index (RSI) 46.75 42.96
Support Level $2.54 $26.67
Resistance Level $2.88 $32.33
Average True Range (ATR) 0.22 3.08
MACD 0.08 -0.59
Stochastic Oscillator 56.98 7.57

Price Performance

Historical Comparison
LAES
FBRX

About LAES SEALSQ Corp

SEALSQ Corp develops certified secure microcontrollers and implements post-quantum cryptography. The company develops solutions including post-quantum microchips and devices that can be used in a variety of applications, from multi-factor authentication, home automation, and IT network infrastructure to automotive, industrial automation, and control systems. The company's vaultIC range offers a set of ready-to-use secure elements designed to implement embedded security for any kind of device with fast time-to-market and high flexibility. The company's products include VaultIC155, VaultIV18x, VaultIC292, and VaultIC40x. The company generates a majority of its revenue from North America, while it also has its presence in Europe, Middle East & Africa, Asia Pacific, and Latin America.

About FBRX Forte Biosciences Inc.

Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Share on Social Networks: